Dov	ic	ion	1
nev	12	1011	

## Cell Signaling **ETO Antibody** #4498 store at -20C H. Orders: 877-616-CELL (2355) orders@cellsignal.com 877-678-TECH (8324) Support: info@cellsignal.com cellsignal.com Web:

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	<b>MW (kDa):</b>	Source/Isotype: Babbit	UniProt ID: #006455	Entrez-Gene Id:	
		Endogenous	00	Kabbit	#000400	002	
Product Usage		Application			Dilution		
Information		Western Blotting			1:1000		
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.					
Specificity/Sen	sitivity	ETO Antibody detects	endogenous levels	of ETO protein.			
Source / Purific	ation	Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to amino acid sequence surrounding Ser270 of human ETO. Antibodies are purified by protein A and peptide affinity chromatography.					
Background		ETO belongs to a family of evolutionarily conserved nuclear factors. Although it has no DNA binding domains it is reported to act as a transcriptional corepressor (1). It is best characterized as the fusion partner of AML1 in acute myeloid leukemia with the t(8;21) translocation which gives rise to the AML-ETO fusion protein (2). AML1 is a transcription factor that is involved in the differentiation of all hematopoietic lineages. The fusion protein lacks the activation domain of AML1 and behaves as a dominant negative AML1, repressing AML1 target genes. AML-ETO also causes activation of other genes through a mechanism that involves Bcl-2 and enhanced expression of p21 waf1/cip1 (3,4). The AML-ETO fusion protein is thought to cause the expansion of a hematopoietic stem cell population that has limited lineage commitment and genomic instability (5). Recent evidence derived from chromatin immunoprecipitation (ChIP) experiments has demonstrated that ETO may play a role in the regulation of Notch target genes, and AML-ETO has been shown to disrupt repression of Notch target genes (6). Therefore, both AML and Notch target genes are deregulated by AML-ETO. Epigenetic silencing of the microRNA-223 gene has also been attributed to activities of AML-ETO, contributing to the differentiation block in t(8;21) leukemia (7).					
Background Re	ferences	1. Davis, J.N. et al. (200 2. Downing, J.R. et al. ( 3. Klampfer, L. et al. (19 4. Peterson, L.F. et al. ( 5. Elagib, K.E. and Golo 6. Salat, D. et al. (2008) 7. Nervi, C. et al. <i>Epige</i>	3) Gene 303, 1-10. 1993) Blood 81, 286 996) Proc Natl Acad 2007) Blood 109, 43 Ifarb, A.N. (2007) Co Mol Cell Biol 28, 35 netics 3, 1-4.	i0-5. <i>Sci USA</i> 93, 14059-64. 392-8. <i>ancer Lett</i> 251, 179-86. 502-12.			
Species Reactiv	vity	Species reactivity is de	termined by testing	g in at least one approve	d application (e.g., v	western blot).	
Western Blot B	uffer	IMPORTANT: For weste TBS, 0.1% Tween® 20 a	ern blots, incubate at 4°C with gentle s	e membrane with diluted primary antibody in 5% w/v BSA, 1X shaking, overnight.			
Applications Ke	ey	W: Western Blotting					
Cross-Reactivit	у Кеу	H: Human M: Mouse R	: Rat <b>Mk:</b> Monkey				
Trademarks an	d Patents	Cell Signaling Technolo	ogy is a trademark	of Cell Signaling Technol	ogy, Inc.		
		All other trademarks a more information.	re the property of t	heir respective owners.	Visit cellsignal.com/	trademarks for	
Limited Uses		Except as otherwise ex the following terms ap terms and conditions t	pressly agreed in a ply to Products pro hat are in addition	writing signed by a lega vided by CST, its affiliate to, or different from, the	ally authorized repressons of the second sec	esentative of CST, Any Customer's n, unless	

separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.